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Abstract
Background: Virological response to antiretroviral treatment (ART) in rural Africa is poorly described. We examined
virological efficacy and emergence of drug resistance in adults receiving first-line ART for up to 4 years in rural Tanzania.
Methods: Haydom Lutheran Hospital has provided ART to HIV-infected patients since October 2003. A combination
of stavudine or zidovudine with lamivudine and either nevirapine or efavirenz is the standard first-line regimen. Nested
in a longitudinal cohort study of patients consecutively starting ART, we carried out a cross-sectional virological efficacy
survey between November 2007 and June 2008. HIV viral load was measured in all adults who had completed at least 6
months first-line ART, and genotypic resistance was determined in patients with viral load >1000 copies/mL.
Results: Virological response was measured in 212 patients, of whom 158 (74.5%) were women, and median age was
35 years (interquartile range [IQR] 29–43). Median follow-up time was 22.3 months (IQR 14.0–29.9). Virological
suppression, defined as <400 copies/mL, was observed in 187 patients (88.2%). Overall, prevalence of ³1 clinically
significant resistance mutation was 3.9, 8.4, 16.7 and 12.5% in patients receiving ART for 1, 2, 3 and 4 years, respectively.
Among those successfully genotyped, the most frequent mutations were M184I/V (64%), conferring resistance to
lamivudine, and K103N (27%), Y181C (27%) and G190A (27%), conferring resistance to non-nucleoside reverse
transcriptase inhibitors (NNRTIs), whereas 23% had thymidine analogue mutations (TAMs), associated with cross-
resistance to all nucleoside reverse transcriptase inhibitors (NRTIs). Dual-class resistance, i.e. resistance to both NRTIs
and NNRTIs, was found in 64%.
Conclusion: Virological suppression rates were good up to 4 years after initiating ART in a rural Tanzanian hospital.
However, drug resistance increased with time, and dual-class resistance was common, raising concerns about exhaustion
of future antiretroviral drug options. This study might provide a useful forecast of drug resistance and demand for
second-line antiretroviral drugs in rural Africa in the coming years.
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Background
Access to antiretroviral treatment (ART) of HIV/AIDS has
increased substantially over the past few years throughout
the developing world. Lower prices of antiretroviral drugs
combined with political determination have given rise to
one of the greatest public health operations of our time,
spearheaded by World Health Organization (WHO), Joint
United Nations Programme on HIV/AIDS (UNAIDS) and
international non-governmental organizations (NGOs).
By December 2007, three million people were receiving
ART in low- and middle-income countries, but still this
was only 31% of those estimated to be in need of it [1].
ART programs in developing countries are now moving
from early pioneer projects to a sustained effort. Inevita-
bly, the long-term challenges of providing ART will
become increasingly evident, including late drug toxici-
ties, treatment failure and emergence of drug resistance [2-
4]. Indeed, some have argued that scaling up ART in Africa
could create widespread drug resistance [5,6]. Early
reports, however, have documented good adherence to
therapy [7] and short-term virological efficacy compara-
ble to industrialized countries [8].
Although several studies on ART efficacy in Africa have
been published, the majority have been carried out in
larger cities [9-11], often with NGO support [10,12], and
usually with short follow-up time [9,10,12]. However, the
majority of Africans reside in rural areas [13], and little is
known about the long-term effects of ART in such settings.
The key to long-term benefit of ART is sustained suppres-
sion of viral replication and avoidance of resistance [14-
16]. Our aim was to assess virological efficacy and emer-
gence of drug resistance in HIV-infected patients up to 4
years after starting first-line ART in a rural Tanzanian hos-
pital.
Methods
Study setting, participants and treatment
Tanzania is a low-income country with an estimated HIV
prevalence of 6.2% [1]. The National AIDS Control Pro-
gram started to scale up antiretroviral treatment from
2005, and by December 2007, 135,696 people were
receiving ART [1]. Haydom Lutheran Hospital is a 400-
bed hospital in Manyara region owned by the Evangelical
Lutheran Church of Tanzania. It is the main health care
provider to a rural population of about 260,000 people.
In 2002, the hospital launched a comprehensive HIV pre-
vention and intervention program, which has previously
been described in detail [17]. In brief, free treatment and
care has been offered to all HIV-infected patients since
October 2003, including free drugs and in-patient care.
Clinical officers have been trained by experienced HIV
physicians to treat and follow-up patients. The HIV pro-
gram in Haydom is now integrated in the National AIDS
Control Program.
All patients were assessed with a standardized evaluation
form at enrolment, where demographic data, medical his-
tory, clinical findings and laboratory investigations were
recorded. ART was initiated in accordance with WHO's
recommendations [18-20]: WHO stage 4 irrespective of
CD4 cell count, WHO stage 3 with CD4 £ 350 cells/mL, or
CD4 £ 200 cells/mL with any WHO stage. However, reliable
CD4 cell counts were not available until September 2006;
thus, most patients started ART based on clinical criteria
only (WHO stage 3 and 4). In addition, triple-drug com-
bination ART, and not single-dose nevirapine, was offered
to HIV-infected pregnant and lactating women, from
pregnancy week 20 till cessation of breast-feeding, irre-
spective of WHO stage and CD4 cell count, to prevent
mother-to-child transmission (PMTCT).
First-line treatment was stavudine or zidovudine, com-
bined with lamivudine, and either nevirapine or efa-
virenz. A generic fixed-dose combination of stavudine,
lamivudine and nevirapine was preferred whenever possi-
ble. Patients with CD4 £ 200 cells/mL or WHO stage 3 or 4
disease were given co-trimoxazole prophylaxis 960 mg
thrice weekly. Second-line treatment was available from
December 2006 and comprised lopinavir/ritonavir, dida-
nosine and abacavir. Criteria for switching to second-line
ART was virological failure as recommended by WHO (i.e.
>10,000 copies/mL) [20]; however, viral load was not
measured routinely, and only selected patients with high
clinical suspicion of failure were tested.
Nested in a longitudinal cohort study of patients consecu-
tively starting ART, we carried out a cross-sectional viro-
logical efficacy survey between November 15, 2007 and
June 6, 2008. All adults (³15 years) who had received first-
line ART for more than 6 months were considered eligible.
Patients were included regardless of previous adherence
or treatment interruptions. However, those who had
stopped ART for ³1 month and not re-started at the time
of the survey were classified as "stopped treatment" and
excluded. Furthermore, those who had already switched
to second-line ART were excluded since genotypic resist-
ance results prior to the switch were unavailable. Ethical
approval was granted by National Institute for Medical
Research in Tanzania and Regional Committee for Medi-
cal Research Ethics in Norway, and all patients gave writ-
ten consent to participate in the study.
Laboratory investigations
Standard laboratory investigations at baseline included:
Full blood cell count, erythrocyte sedimentation rate, liver
function tests, creatinine, blood sugar, hepatitis B surface
antigen and syphilis serology. Patients who started ART
were followed up with laboratory investigations every
three months. Hematology was measured using the Sys-
mex KX-21 Hematology Analyzer (Sysmex Corp., Kobe,
Japan). CD4 cell counts were available from SeptemberBMC Infectious Diseases 2009, 9:108 http://www.biomedcentral.com/1471-2334/9/108
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2006 using the FACSCount flow cytometer (Becton Dick-
inson, San Jose, California, USA).
Plasma specimens for virological analyses were stored at -
20°C until shipment to the reference laboratory. Manu-
facturer's instructions were followed with regard to sam-
ple collection and transport. HIV viral load was measured
at Muhimbili National Hospital, Dar es Salaam, Tanzania,
using the Cobas TaqMan 48 Analyzer (Roche Diagnostics,
Branchburg, New Jersey, USA) with a lower detection
limit at 40 copies/mL; however, due to equipment break-
down, one third of the samples were analysed with the
Cobas Amplicor HIV-1 Monitor v1.5 (Roche Diagnostics,
Branchburg, New Jersey, USA) with a detection limit at
400 copies/mL. All specimens with viral load >1000 cop-
ies/mL were sent to Ulleval University Hospital, Oslo,
Norway, for genotypic resistance testing. The ViroSeq
HIV-1 Genotyping System (Abbott Molecular, De Plains,
Illinois, USA) was used to determine HIV-1 subtype and
mutations in the protease and reverse transcriptase genes.
Only drug resistance mutations listed in the Spring 2008
update from the International AIDS Society were consid-
ered [21]. Resistance profiles to antiretroviral drugs were
interpreted according to the Stanford University HIV Drug
Resistance Database (HIVdb Program, http://hivdb.stan
ford.edu).
Statistical analysis
The main outcomes of interest were on-treatment virolog-
ical suppression and clinically significant genotypic resist-
ance. Virological suppression was defined as HIV viral
load <400 copies/mL, since this was the detection limit of
the least sensitive assay used in this study. Clinically sig-
nificant genotypic resistance was defined as HIV viral load
>1000 copies/mL and presence of ³1 drug resistance
mutation listed in the Spring 2008 update from the Inter-
national AIDS Society [21]. Duration of ART was rounded
off to the nearest full year (1, 2, 3 or 4 years) when pre-
senting prevalence of virological suppression and drug
resistance. Logistic regression was used to study associa-
tions between baseline characteristics and emergence of
drug resistance. Univariable analysis was performed for
the following variables: Sex, age, WHO stage, initial ART
regimen, duration of ART, body mass index, hemoglobin
level and total lymphocyte count. CD4 cell counts were
excluded because of too few observations. Variables with
P < 0.1 in univariable analyses were advanced into a mul-
tivariable regression analysis, using the forward stepwise
(Wald) method to avoid overcorrection. Multicollinearity
was excluded using Spearman's correlation coefficient
with a cutoff at 0.7. Data were analysed with SPSS version
16.0 for Windows (SPSS Inc., Chicago, Illinois, USA),
except 95% confidence intervals (CI) for proportions
which were calculated with NCSS version 2007 (NCSS,
Kaysville, Utah, USA). All tests were two-sided and level of
significance was set at P < 0.05.
Results
Baseline characteristics
Out of 549 adults who enrolled in the HIV program and
started ART, 126 patients (23.0%) died, of whom 76 died
within 3 months of starting ART. Seventy-nine patients
(14.4%) were transferred to another health facility, 46
(8.4%) were lost to follow-up, whereas 27 patients (4.9%)
self-stopped treatment after receiving ART for a median of
11.3 months. Fifty patients were not eligible for the viro-
logical survey because they had taken ART for less than 6
months, and 3 because they were on second-line ART.
Among the remaining 218 patients who were selected for
the survey, plasma was obtained from 212 of them. Six
patients failed to participate due to: Temporary travel to
another area (n = 3), error in specimen preparation (n = 1)
or unknown (n = 2). The study profile is presented in fig-
ure 1.
Median follow-up time among 212 patients included in
this study was 22.3 months (interquartile range [IQR]
14.0–29.9). Median age was 35 years (IQR 29–43), and
158 patients (74.5%) were women. At the time of ART ini-
tiation, 110 (52.1%) had clinical AIDS (WHO stage 4).
The most common AIDS defining events were: Wasting
syndrome (87.3%), oesophageal candidiasis (10.9%),
Profile of the study cohort, Haydom Lutheran Hospital, Tan- zania, 2003–08 Figure 1
Profile of the study cohort, Haydom Lutheran Hospi-
tal, Tanzania, 2003–08.
549 adults who started 
ART
271 adults on ART alive 
and in care
212 obtained viral load
187 with viral load 
<400 copies/ml
25 with viral load  
>400 copies/ml
126 died
79 transferred out
46 lost to follow-up
27 stopped treatment
50 on ART <6 months
3 on second-line ART
6 unable to obtain viral 
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extrapulmonary tuberculosis (4.5%) and Kaposi's sar-
coma (4.5%). Initial ART regimen was stavudine/lamivu-
dine/nevirapine in 122 patients (57.5%), stavudine/
lamivudine/efavirenz in 39 (18.4%), zidovudine/lamivu-
dine/nevirapine in 45 (21.2%), and zidovudine/lamivu-
dine/efavirenz in 6 (2.8%). Among 66 patients with a
baseline CD4 measurement, median CD4 cell count was
118 cells/mL (IQR 51–189).
Virological results
Overall, 187 patients (88.2%; 95% CI 83.1–92.2) had
suppressed viraemia (<400 copies/mL). Two patients
(0.9%) had 400–1000 copies/mL, 14 (6.6%) had 1000–
10,000 copies/mL, 5 (2.4%) had 10,000–100,000 copies/
mL, and 4 (1.9%) had >100,000 copies/mL. The propor-
tion of patients (95% CI) with suppressed viraemia after
1, 2, 3 and 4 years was 94.8% (87.2–98.6), 88.0% (79.0–
94.1), 75.0% (57.8–87.9) and 87.5% (61.7–98.4), respec-
tively (figure 2). The small number of patients who
received ART for 3 and 4 years (n = 36 and n = 16, respec-
tively) gave rise to wide confidence intervals for those
groups.
Genotyping was successful in 22 of 23 samples with viral
load >1000 copies/mL. HIV-1 subtypes were A (n = 3), C
(n = 7), D (n = 8) and CRF01_AE (n = 2), whereas 2 were
inconclusive (different subtypes in the protease and
reverse transcriptase genes). Among those successfully
genotyped, 18 patients (82%) harboured at least one clin-
ically relevant resistance mutation in the reverse tran-
scriptase gene (table 1). The most frequent mutations
were M184I/V (n = 14; 64%), conferring resistance to lam-
ivudine, and K103N (n = 6; 27%), Y181C (n = 6; 27%)
and G190A (n = 6; 27%), conferring resistance to non-
nucleoside reverse transcriptase inhibitors (NNRTIs). Thy-
midine analogue mutations (TAMs), associated with
cross-resistance to all nucleoside reverse transcriptase
inhibitors (NRTIs), were found in 5 patients (23%), of
whom 1 had ³3 TAMs. Fourteen patients (64%) had dual-
class resistance, i.e. resistance to both NRTIs and NNRTIs.
None had clinically relevant mutations in the protease
gene.
Hence, in total, 18 of 212 patients (8.5%; 95% CI 5.1–
13.1) harboured drug resistance by use of a standard gen-
otyping assay. The prevalence (95% CI) of any clinically
significant drug resistance after 1, 2, 3 and 4 years was
3.9% (0.8–11.0), 8.4% (3.5–16.6), 16.7% (6.4–32.8) and
12.5% (1.6–38.3), respectively (figure 2). Dual-class
resistance was observed in 3.9% (0.8–11.0), 6.0% (2.0–
13.5), 13.9% (4.7–29.5) and 6.3% (0.2–30.2), respec-
tively. Again, the small number of patients on ART for 3
and 4 years gave rise to wide confidence intervals.
Predictors of drug resistance
In univariable logistic regression analysis only duration of
ART was significantly associated with emergence of drug
resistance (³3 years on ART; odds ratio [OR] 4.49; 95% CI
1.13–17.8; P = 0.033). Anemia (hemoglobin <10 g/dL;
OR 2.84; 95% CI 0.97–8.32; P = 0.058) and lymphopenia
(total lymphocyte count <1.2 × 109/L; OR 2.91; 95% CI
0.99–8.53;  P  = 0.052) were borderline significant. No
associations were found for age, sex, clinical stage, body
mass index or initial ART regimen. In multivariable anal-
ysis where duration of ART, anemia and lymphopenia
were included using the forward stepwise method, only
duration of ART remained in the final model, with the
same odds ratio and P-value as above (table 2).
Two patients with low-level viraemia (400–1000 copies/
mL) and one patient whose genotyping failed were
assumed not to harbour resistance in our study. To assess
whether this assumption might have biased our results,
we conducted a sensitivity analysis where these patients
were classified as resistant. In the resulting multivariable
model, both duration of ART (³3 years on ART; OR 6.47;
95% CI 1.28–32.6; P = 0.024) and lymphopenia (total
lymphocyte count <1.2 × 109/L; OR 4.24; 95% CI 1.48–
12.2; P = 0.007) were significantly associated with resist-
ance. Hence, the effect of lymphopenia might have been
Proportion of patients on ART with: A) suppressed viraemia  (<400 copies/mL), and B) ³1 clinically significant resistance  mutation Figure 2
Proportion of patients on ART with: A) suppressed 
viraemia (<400 copies/mL), and B) ³1 clinically signif-
icant resistance mutation. Vertical lines indicate 95% 
confidence interval.
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underestimated by misclassification bias in the main anal-
ysis, whereas duration of ART was a strong and significant
predictor of resistance in both analyses.
Discussion
Virological suppression rates were good up to 4 years after
starting ART in a rural Tanzanian hospital. These results
are in keeping with early reports from resource-limited
settings, where short-term virological efficacy rates were as
good as those reported from Europe and North America
[8]. We show that suppression of viraemia can be sus-
tained for several years even in rural Africa, where logisti-
cal support is challenging and patients often live in
poverty. However, like in many other African ART pro-
grams the attrition rate was high, and strategies to reduce
early mortality and other program losses need to be iden-
tified [11,12,22,23].
Experiences elsewhere have shown that poorly managed
HIV programs can give rise to widespread drug resistance
[24]. A number of factors may have contributed to the sus-
tained virological efficacy of the ART program in the
present study. First, all treatment and care for HIV-
infected patients was provided free of charge, which has
previously been shown to improve treatment efficacy [8].
Second, all patients had three days of adherence counsel-
ling with a nurse prior to starting ART. Third, a close col-
laboration between the clinical staff and a network of
community home-based carers ensured follow-up of
patients in their villages. Fourth, regular educational peer-
Table 1: Genotypic resistance results in 23 patients on ART with virological failure (HIV-1 RNA >1000 copies/mL)
ID Sex Age ART regimen: initial 
(currenta)
Months on ART Subtype Viral load Protease mutations Reverse transcriptase 
mutations
34 M 24 ZDV/3TC/NVP 
(ZDV/3TC/EFV)
42.1 C 434,131 M36I, L63P, H69K, I93L K103N
84 M 30 d4T/3TC/EFV 
(d4T/3TC/NVP)
49.1 D 8690 I13V, L33V, M36I, I64V K103N, M184V
224 M 32 d4T/3TC/NVP 34.7 C 1349 M36I, L63P, H69K, I93L
240 M 43 d4T/3TC/EFV 
(d4T/3TC/NVP)
35.5 CRF01_AE 81,691 I13V, M36I, L63P, H69K D67N, K70R, K103N, 
V179T, M184V, K219Q
275 F 41 d4T/3TC/NVP 32.3 D 477,518 I13V, K20R, M36V, L63P, 
I64V, I93L
G190A
282 F 32 d4T/3TC/NVP 32.4 A 2621 L10I, I13V, M36I, H69K M184V, Y188C
307 F 35 d4T/3TC/NVP 
(d4T/3TC/EFV)
31.7 Failed 2301 Failed Failed
321 F 34 d4T/3TC/NVP 30.4 D 1504 I13V, K20R, M36I, I62V, 
I64V
Y181C, M184I
366 F 48 d4T/3TC/NVP 28.3 C 3000 M36I, H69K, I93L K103N, V179T, M184V
401 F 44 d4T/3TC/NVP 28.6 C 2290 M36I, D60E, H69K, I93L G190A
402 F 40 d4T/3TC/NVP 
(d4T/3TC/EFV)
28.3 ?b 20,500 L10I, I13V, G16E, M36I, 
H69K
K101P, M184V, G190A, 
T215F
410 F 45 d4T/3TC/NVP 36.9 D 5990 I13V, L63P, I64V, V77I K101E, M184V, G190A
473 F 35 d4T/3TC/NVP 27.3 D 3965 I13V, I64V, V77I M41L, V75I, Y181C, M184V
476 F 19 ZDV/3TC/NVP 
(d4T/3TC/NVP)
26.5 D 1980 I64V G190A
516 F 24 d4T/3TC/EFV 24.0 C 419,979 M36I, L63P, H69K, I93L
554 F 28 ZDV/3TC/NVP 
(d4T/3TC/NVP)
24.0 C 1886 K20R, M36I, H69K
583 F 30 d4T/3TC/NVP 21.1 CRF01_AE 1432 L10V, G16E, M36IV, 
H69K
K103N, Y181C, M184V
611 F 33 d4T/3TC/NVP 17.8 C 15,600 M36I, I62V, L63P, H69K, 
V82I, I93L
K65R, V75I, V108I, Y181C, 
M184V, L210W
643 F 37 d4T/3TC/NVP 31.3 D 2400 K20R, M36I, I62V, I64M K70R, Y181C, M184V
749 F 32 d4T/3TC/EFV 
(d4T/3TC/NVP)
19.0 ?c 35,400 I13V, M36I, H69K K103N, M184V
752 F 35 d4T/3TC/NVP 14.5 A 3101 L10I, M36I, H69K Y181C, M184V
785 F 26 d4T/3TC/NVP 
(d4T/3TC/EFV)
14.6 D 3,683,117 I13V, M36I, D60E, I64V
982 F 15 d4T/3TC/NVP 8.5 A 76,700 I13V, M36I, L63P, H69K, 
V82I
V179T, M184V, G190A
aOnly specified if different from initial regimen.bCRF_01AE in the protease and A in the reverse transcriptase gene. cA in the protease and 
CRF_01AE in the reverse transcriptase gene.
ART, antiretroviral treatment; d4T, stavudine; 3TC, lamivudine; NVP, nevirapine; EFV, efavirenz; ZDV, zidovudine.BMC Infectious Diseases 2009, 9:108 http://www.biomedcentral.com/1471-2334/9/108
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support meetings contributed to reduce the stigma and
isolation many patients experience after receiving an HIV
diagnosis. Fifth, antiretroviral drug supply continuity was
uninterrupted from the beginning of the program. And
finally, visiting HIV physicians focused on capacity build-
ing of local clinical officers, with emphasis on common
curable opportunistic infections, such as tuberculosis,
candidiasis, cryptococcal meningitis and cerebral toxo-
plasmosis.
Overall, emergence of drug resistance was relatively
uncommon; only 8.5% harboured clinically significant
resistance mutations. Although the proportion of patients
with drug resistance was low, however, in a high-preva-
lence country like Tanzania the absolute number of indi-
viduals in need of second-line ART can rapidly become
substantial. If our results were extrapolated to Tanzania as
of December 2007 [1], then 11,500 patients would har-
bour drug resistance and be in need of second-line ART.
Such an extrapolation is not necessarily valid, but it illus-
trates the magnitude of the problem that drug resistance
can inflict on national ART programs. The number of indi-
viduals receiving ART has increased 20-fold over the past
4 years in sub-Saharan Africa [1], but access to second-line
antiretroviral drugs is still limited in many developing
countries due to higher costs and lack of fixed-dose com-
binations. Our study underscores the growing global need
for affordable and convenient second-line antiretroviral
regimens.
The prevalence of drug resistance increased with time and
reached approximately 15% after 3–4 years on ART. Most
previous studies on ART in Africa have focused on early
treatment efficacy, showing good virological results with a
limited observation time [10,12,25]. Only a few studies
have assessed long-term (>2 years) emergence of drug
resistance in sub-Saharan Africa. An early study from Sen-
egal showed that 12.5% had one or more drug resistance
mutations after a median of 30 months on ART [26],
whereas a recent study from Côte d'Ivoire found 22%
resistance after a median of 37 months on ART [27]. These
results should not be used as an argument against HIV
treatment in Africa; in fact, the results are comparable to a
recent study from Canada, where 20% developed resist-
ance after 30 months on the ART regimen most widely
used in resource-limited settings (stavudine/lamivudine/
nevirapine) [28]. Thus, emergence of drug resistance
appears to occur at a similar rate in Africa as in a Western
setting.
Of concern, among 18 patients with drug resistance muta-
tions, 14 harboured dual-class resistance. All 14 had a
combination of M184I/V, conferring resistance to lamivu-
dine, with one or more of K103N, Y181C and G190A,
conferring resistance to NNRTIs. Five of these patients
also had thymidine analogue mutations (TAMs), associ-
ated with cross-resistance to all NRTIs. In 3 patients the
standard second-line regimen in Tanzania would not be
adequate, i.e. would not introduce at least 2 fully active
drugs, which is the recommended strategy in treatment
failure [29]. Other studies from low- and middle-income
countries, using the same first-line treatment, have found
a similar pattern. In a recent study from Angola, 65% of
patients with virological failure had dual-class resistance
[30]. Furthermore, a study from Thailand found that sec-
ond-line treatment options, in the absence of newer
antiretroviral drugs, were limited for 48% of patients fail-
ing their initial regimen [31]. Expanding access to newer
antiretroviral drugs, including new HIV drug classes,
should be a priority in the global efforts to control HIV/
AIDS.
Table 2: Predictors of drug resistance in 212 HIV-infected adults on ART in rural Tanzania
Univariablea Multivariableb
Predictor variables OR (95% CI) P OR (95% CI) P
Duration of ART
1 year 1 1
2 years 2.27 (0.57–9.12) 0.247 2.27 (0.57–9.12) 0.247
³ 3 years 4.49 (1.13–17.8) 0.033 4.49 (1.13–17.8) 0.033
Hemoglobin
³ 10 g/dL 1
<10 g/dL 2.84 (0.97–8.32) 0.058 NS
Total lymphocyte count
³ 1.2 × 109/L 1
<1.2 × 109/L 2.91 (0.99–8.53) 0.052 NS
a No significant associations were found for age, sex, clinical stage, body mass index or initial ART regimen.
bStepwise multivariable logistic regression using a forward selection procedure. NS denotes that the variable did not meet the significance level 
criterion (P <0.05) for inclusion in the final model.
OR, odds ratio; CI, confidence interval; ART, antiretroviral therapy.BMC Infectious Diseases 2009, 9:108 http://www.biomedcentral.com/1471-2334/9/108
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It has been shown that in the presence of a failing ART reg-
imen, resistance mutations accumulate, jeopardizing
future treatment options [32]. Early detection of treat-
ment failure rely on viral load measurements, a standard
component of ART programs in resource-rich countries
[29]. In the present program, like in most resource-limited
settings, viral load was not measured routinely, and treat-
ment failure had to be assessed by clinical signs and CD4
cell counts. However, clinical signs and CD4 decline, as
recommended by WHO to detect treatment failure in the
absence of viral loads, have poor sensitivity and specifi-
city, and result in frequent misclassifications [33,34].
Hence, there is an urgent need for a simple, affordable
viral load assay adapted for use in basic, tropical environ-
ments, so that treatment failure can be detected before
multiple mutations occur.
In our study only duration of ART was significantly asso-
ciated with emergence of drug resistance. Baseline anemia
and lymphopenia were borderline significant in univaria-
ble analysis, and our sample size might have been too
small to reveal a true association. Other studies have
found that low CD4 cell count and high viral load at base-
line increase the risk of drug resistance [35]; however,
these measurements were not available in our study.
There were some weaknesses of this study. First, virologi-
cal efficacy could only be assessed in patients who were
alive and in care. A high early mortality accounted for
most of the program loss, which probably reflected
advanced immunodeficiency at enrolment rather than
treatment failure [17]. Many patients were transferred out
when the National AIDS Control Program started scaling
up ART in other villages, but it is unlikely that this intro-
duced any systematic bias. Among patients who stopped
treatment (4.9%) or were lost to follow-up (8.4%), there
was probably a proportion who either died or developed
drug resistance. Our study must be considered an "on-
treatment" analysis, and virological suppression rates and
resistance estimates in an "intention-to-treat" analysis
would have been poorer. Another limitation of this study
was the lack of longitudinal viral load and resistance
results. A cross-sectional virological survey may be more
influenced by random biological variations and labora-
tory artefacts, being derived from a single time point. Also,
we can not ascertain whether drug resistance mutations
existed prior to initiation of ART, which was recently
observed in rural South Africa [36], or developed during
treatment. However, Haydom Lutheran Hospital was the
first ART provider in the area, and single-dose nevirapine
was not used for PMTCT, so it is unlikely that there was
any significant primary resistance. Furthermore, this study
was limited by lack of adherence data, which is considered
the most important predictor of resistance [35]; however,
adherence estimates would not have altered our conclu-
sions. Finally, this was a hospital based study and proba-
bly there was a selection bias towards more advanced
immunodeficiency at baseline, which has previously been
shown to increase the risk of drug resistance [35]. On the
other hand, late presentation has been observed in many
African ART programs [10-12,25,37,38], and we believe
our findings can be representative of other similar set-
tings.
Conclusion
We found good virological suppression rates up to 4 years
after initiating ART in a rural hospital in Tanzania. These
results suggest that ART can be safely scaled up in rural
Africa with similar long-term virological efficacy rates as
those reported for industrialized countries. However,
prevalence of drug resistance increased with time, and
dual-class resistance was common, raising concerns about
exhaustion of future antiretroviral drug options. Earlier
detection of treatment failure and timely switch to sec-
ond-line ART could reduce accumulation of drug resist-
ance, underscoring the growing need for virological
monitoring in resource-limited settings. This study might
provide a useful forecast of drug resistance and demand
for second-line antiretroviral drugs in rural Africa in the
coming years.
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